Interferon-beta therapy for multiple sclerosis - Is the injection site the relevant action site?

Journal of Neuroimmunology

Volumn 215, Issue 1-2, 2009, Pages 117-121

  Smith, Derek ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dendritic cells; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DENDRITIC CELL; DISABILITY; DRUG MECHANISM; HUMAN; HYPOTHESIS; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INJECTION SITE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; T LYMPHOCYTE;

ANIMALS; DENDRITIC CELLS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MULTIPLE SCLEROSIS; SKIN;

EID: 70349747277     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.08.011     Document Type: Review

References (59)

1. Balashov K.E., Smith D.R., Khoury S.J., Hafler D.A., and Weiner H.L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD 4 ligand. Proc. Natl. Acad. Sci. 94 (1997) 599-603
2. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
3. Bartholome E.J., Willems F., Crusiaux A., Thielemans K., Schandene L., and Goldman M. IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. J. Interferon Cytokine Res. 19 (1999) 471-478
4. Betaseron [package insert]. 2008. Bayer HealthCare Pharmaceuticals Inc. Montville, NJ.
5. Bos J.D. Skin Immune System (2004), CRC Press, New York, NY
6. Buchwalder P.A., Buclin T., Trinchard I., Munafo A., and Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 20 (2000) 857-866
7. Buttmann M., Goebeler M., Toksoy A., Schmid S., Graf W., Berberich-Siebelt F., and Rieckmann P. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J. Neuroimmunol. 168 (2005) 175-182
8. Calabresi P.A., Pelfrey C.M., Tranquill L.R., Maloni H., and McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 49 (1997) 1111-1116
9. Chiang J., Gloff C.A., Yoshizawa C.N., and Williams G.J. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm. Res. 10 (1993) 567-572
10. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 79 (2007) 43-72
11. Cravens P.D., and Lipsky P.E. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol. Cell Biol. 80 (2002) 497-505
12. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., and Sedgewick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
13. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., Ferrero B., Eid P., and Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann. Neurol. 65 (2009) 499-509
14. Fajardo-Moser M., Berzel S., and Moll H. Mechanisms of dendritic cell-based vaccination against infection. Int. J. Med. Microbiol. 298 (2008) 11-20
15. Fujita H., Asahina A., Tada Y., Fujiwara H., and Tamaki K. Type I interferons inhibit maturation and activation of mouse Langerhans cells. J. Invest. Dermatol. 125 (2005) 126-133
16. Furuzawa-Carballeda J., Vargas-Rojas M.I., and Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun. Rev. 6 (2007) 169-175
17. Gigli G., Caielli S., Cutuli D., and Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 122 (2007) 409-417
18. Huang Y.M., Hussien Y., Yarilin D., Xiao B.G., Liu Y.J., and Link H. Interferon-beta induces the development of type 2 dendritic cells. Cytokine 13 (2001) 264-271
19. Hussien Y., Sanna A., Soderstrom M., Link H., and Huang Y.M. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J. Neuroimmunol. 121 (2001) 102-110
20. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., and Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343 (2000) 898-904
21. Jacobs L.D., Cookfair D.L., Rudick R.A., et al., The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39 (1996) 285-294
22. Janeway Jr. C.A., Travers P., Walport M., and Schlomchik M.J. T cell-mediated immunity. Immunobiology (2005), Garland Science, New York, NY
23. Kappos L., Freedman M.S., Polman C.H., et al., BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
24. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., Khoury S.H., and Weiner H.L. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177 (2006) 4196-4202
25. Krakauer M., Sorensen P., Khademi M., Olsson T., and Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult. Scler. 14 (2008) 622-630
26. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., and Nicholson L.B. T-cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T-cell repertoire. Annu. Rev. Immunol. 20 (2002) 101-123
27. Kupper T.S., and Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4 (2004) 211-222
28. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
29. Larregina A.T., and Falo Jr. L.D. Changing paradigms in cutaneous immunology: adapting with dendritic cells. J. Invest. Dermatol. 124 (2005) 1-12
30. Lee H.K., and Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin. Immunol. 19 (2007) 48-55
31. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40 (1996) 846-852
32. Li Y., Chu N., Hu A., Gran B., Rostami A., and Zhang G.X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 130 (2007) 490-501
33. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalitis. Nat. Med. 8 (2002) 500-508
34. Martín-Saavedra F.M., González-García C., Bravo B., and Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 45 (2008) 4008-4019
35. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8 (2007) 913-919
36. McGeachy M.J., and Cua D.J. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin. Immunol. 19 (2007) 372-376
37. McRae B.L., Semnani R.T., Hayes M.P., and van Seventer G.A. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160 (1998) 4298-4304
38. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001) 255-258
39. Miller L.S., and Modlin R.L. Toll-like receptors in the skin. Semin. Immunopathol. 29 (2007) 15-26
40. Nagai T., Devergne O., van Seventer G.A., and van Seventer J.M. Interferon-beta mediates opposing effects on interferon-gamma-dependent interleukin-12 p70 secretion by human monocyte-derived dendritic cells. Scand. J. Immunol. 65 (2007) 107-117
41. Nestle F.O., Zheng X.G., Thompson C.B., Turka L.A., and Nickoloff B.J. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151 (1993) 6535-6545
42. Nestle F.O., and Nickoloff B.J. Deepening our understanding of immune sentinels in the skin. J. Clin. Invest. 117 (2007) 2382-2385
43. Neuhaus O., Kieseier B.C., and Hartung H.P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J. Neurol. Sci. 259 (2007) 27-37
44. Pashenkov M., Teleshova N., Kouwenhoven M., Kostulas V., Huang Y.M., Soderstrom M., and Link H. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin. Exp. Immunol. 127 (2002) 519-526
45. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
46. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., and Lui Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
47. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug Medendorp S., Lehmann P., and Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40 (1996) 618-627
48. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T-cell-mediated tissue damage. Nat. Med. 13 (2007) 139-145
49. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., and Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40 (1996) 853-863
50. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45 (1995) 1277-1285
51. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liquori M., Santacroce M.P., Paolicelli D., Guiliani F., Riccio P., and Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53 (1999) 1402-1408
52. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., and Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172 (2008) 146-155
53. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176 (2006) 7768-7774
54. Vaknin-Dembinsky A., Murugaiyan G., Hafler D.A., Astier A.L., and Weiner H.L. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J. Neuroimmunol. 195 (2008) 140-145
55. Valladeau J., and Saeland S. Cutaneous dendritic cells. Semin. Immunol. 17 (2005) 273-283
56. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., and Stockinger B. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (2008) 106-109
57. Wiesemann E., Sonmez D., Heidenreich F., and Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T cells. J. Neuroimmunol. 123 (2002) 160-169
58. Zang Y.C., Skinner S.M., Robinson R.R., Li S., Rivera V.M., Hutton G.J., and Zhang J.Z. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult. Scler. 10 (2004) 499-506
59. Zhang X., Jin J., Tang Y., Speer D., Sujkowska D., and Markovic-Plese S. IFN-beta 1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol. 182 (2009) 3928-3936